Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Liew

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|October 6, 2023
Targeting APRIL in the Treatment of IgA NephropathyChee Kay Cheung, Jonathan Barratt, Kevin Carroll, et al.
The New England Journal of Medicine|October 26, 2024
Atrasentan in Patients with IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Cardiovascular Diabetology|September 16, 2023
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney diseaseJ David Smeijer, Donald E Kohan, Peter Rossing, et al.
Kidney International Reports|July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Kidney International Reports|April 30, 2025
Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial CohortsSean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 12, 2024
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled TrialJonathan Barratt, Adrian Liew, See Cheng Yeo, et al.
Kidney International|February 2, 2023
Home dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceJeffrey Perl, Edwina A Brown, Christopher T Chan, et al.
Kidney International Reports|March 16, 2022
The COVID-19 Pandemic Identifies Significant Global Inequities in Hemodialysis Care in Low and Lower-Middle Income Countries-An ISN/DOPPS SurveyElliot Koranteng Tannor, Brian Bieber, Ryan Aylward, et al.
Kidney International Reports|January 15, 2025
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Kidney International Reports|April 30, 2025
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226]Hiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Clinical Journal of the American Society of Nephrology : CJASN|October 6, 2023
Targeting APRIL in the Treatment of IgA NephropathyChee Kay Cheung, Jonathan Barratt, Kevin Carroll, et al.
The New England Journal of Medicine|October 26, 2024
Atrasentan in Patients with IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Cardiovascular Diabetology|September 16, 2023
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney diseaseJ David Smeijer, Donald E Kohan, Peter Rossing, et al.
Kidney International Reports|July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Kidney International Reports|April 30, 2025
Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial CohortsSean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 12, 2024
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled TrialJonathan Barratt, Adrian Liew, See Cheng Yeo, et al.
Kidney International|February 2, 2023
Home dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceJeffrey Perl, Edwina A Brown, Christopher T Chan, et al.
Kidney International Reports|March 16, 2022
The COVID-19 Pandemic Identifies Significant Global Inequities in Hemodialysis Care in Low and Lower-Middle Income Countries-An ISN/DOPPS SurveyElliot Koranteng Tannor, Brian Bieber, Ryan Aylward, et al.
Kidney International Reports|January 15, 2025
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Kidney International Reports|April 30, 2025
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226]Hiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Pageof 8